Close

Amgen, MGH, Broad Institute to discover new drugs to treat inflammatory bowel disease

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Fluid Path Integrity: Ensuring Purity in Biomanufacturing

In the high-stakes arena of biomanufacturing, where tiny contaminants...

Smart Sensors in Biomanufacturing Transform Fluid Monitoring

Smart Sensors & Monitoring in Fluid Systems in Biomanufacturing Precision...

Revolutionary Drug Delivery System With Nanoparticle Tech

When Willus Fisher, a doctorate candidate at the University...

Revolutionizing Biologics : Inhalation And Liquid Delivery

It is noteworthy that the pharmaceutical industry is gradually...

Amgen (AMGN), Massachusetts General Hospital (MGH) and the Broad Institute have entered inot a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD).

The collaboration will leverage the shared expertise of its participating scientists and partner institutions to discover and develop novel therapies for IBD.

It brings together scientists with expertise in clinical medicine, IBD biology, human genetics, genomic technology as well as drug discovery to work together to help create a new world of therapeutic options for IBD patients.

Under the MGH-Broad-Amgen collaboration, patient DNA samples will be collected and analyzed to identify and further validate genetic targets, biological assays to probe gene function, and subsequent drug discovery and development activities.

A new joint steering committee will be formed under the collaboration in order to select and guide projects.

 

Latest stories